Effectiveness

有效性
  • 文章类型: Journal Article
    基于需求适应方法,延迟使用抗精神病药物有助于识别可能不需要的首发精神病(FEP)青少年.然而,有些人可能需要抗精神病药,推迟可能会损害他们的预后。这项基于全国注册的后续行动旨在检验这两个假设。
    从国家登记册中确定了2003年至2013年间芬兰13-20岁患有精神病(ICD-10代码:F20-F29)的所有青少年(n=6354)。对于每种情况,从精神病发作或直至死亡建立了固定的1825天随访期.如果青少年在随访的最后一年没有死亡并且没有接受精神病治疗和/或残疾津贴,则结果被认为是“良好”。测试第一个假设涉及所有抗精神病治疗的未使用FEP的青少年(n=3714)。第二个假设仅在随访期间接受抗精神病药的子样本中进行了测试(n=3258)。为了解释基线混杂因素,通过具有logit链接函数的治疗加权广义线性模型的稳定逆概率检验假设。
    精神病发作后立即接受抗精神病药物治疗与5年预后不良相关(校正比值比[aOR]:1.8,95%CI:1.6-2.1)。在最终接受抗精神病药物治疗的患者中,抗精神病药物推迟治疗与治疗结果之间没有统计学上的显着关联(aOR:1.02,95%CI:0.7-1.2,P:.8),因此不能为第二种假设提供支持。
    有一个重要的青少年精神病亚组,不需要立即抗精神病药物治疗。需要更稳健的设计来评估观察到的关联的因果关系。
    UNASSIGNED: Based on the need-adapted approach, delaying antipsychotics could help identify first-episode psychosis (FEP) adolescents who might not require them. However, some individuals might need antipsychotics, and postponing could harm their prognosis. This nationwide register-based follow-up aimed to test these two hypotheses.
    UNASSIGNED: All adolescents aged 13-20 with a psychotic disorder (ICD-10 codes: F20-F29) in Finland between 2003 and 2013 were identified (n = 6354) from national registers. For each case, a fixed 1825-day follow-up period was established from the onset of psychosis or until death. The outcome was considered \"good\" if adolescents did not die and had not received psychiatric treatment and/or disability allowances during the final year of follow-up. Testing the first hypothesis involved all antipsychotic treatment-naïve adolescents with FEP (n = 3714). The second hypothesis was tested with a sub-sample of only those who had received antipsychotics during follow-up (n = 3258). To account for baseline confounders, hypotheses were tested via a stabilized inverse probability of treatment weighted generalized linear models with logit link function.
    UNASSIGNED: Immediate antipsychotic treatment after the onset of psychosis was associated with poor 5-year outcome (adjusted odds ratio [aOR]: 1.8, 95% CI: 1.6-2.1). There was no statistically significant association between antipsychotic postponement and treatment outcome in those who eventually received antipsychotic treatment (aOR: 1.02, 95% CI: 0.7-1.2, P: .8), thus not providing support for second hypothesis.
    UNASSIGNED: There is a significant subgroup of adolescent with psychosis who do not require immediate antipsychotic treatment. A more robust design is needed to evaluate the causality of the observed association.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    评估巴洛沙韦(baloxavir)和奥司他韦在中国儿科流感患者中的安全性和有效性。
    在2023年3月至2023年12月期间,在中国复旦大学儿童医院确定了与流感相关的门诊就诊后48小时内服用巴洛沙韦或奥司他韦处方的患者。在抗病毒治疗后评估结果,包括不良反应的发生率以及发热和其他流感症状的持续时间。
    共收集了1430例感染甲型流感的患者,最终包括865例患者(巴洛沙韦:n=420;奥司他韦:n=445)。巴洛他韦组恶心呕吐不良反应发生率(2.38%)与奥司他韦组(12.13%)比较差异有统计学意义[P<0.001,OR=4.2526,95CI(2.0549,9.6080)]。两组患者在其他不良反应方面无明显差异。巴洛他韦组平均发热持续时间(1.43d)明显短于奥司他韦组(2.31d)[P<0.001,95CI(0.7815,0.9917)]。鼻塞和流涕的平均持续时间没有差异,喉咙痛,咳嗽,两组之间的肌肉酸痛。
    与奥司他韦相比,巴洛沙韦的恶心和呕吐发生率较低,巴洛沙韦完全退烧的持续时间比奥司他韦更短。结果表明,巴洛沙韦在中国儿童中具有良好的耐受性和有效性。
    UNASSIGNED: To evaluate the safety and effectiveness of baloxavir marboxil (baloxavir) and oseltamivir in pediatric influenza patients in China.
    UNASSIGNED: Patients filling a prescription for baloxavir or oseltamivir within 48 h following an influenza-related outpatient visit were identified in Children\'s Hospital of Fudan University in China between March 2023 and December 2023. Outcomes were assessed after antiviral treatment and included the incidence of adverse reactions and the duration of fever and other flu symptoms.
    UNASSIGNED: A total of 1430 patients infected with influenza A were collected and 865 patients (baloxavir: n = 420; oseltamivir: n = 445) finally included. The incidence of adverse reactions of nausea and vomiting was significantly different between the baloxavir group (2.38%) and the oseltamivir group (12.13%) [P < 0.001, OR = 4.2526, 95%CI (2.0549, 9.6080)]. No differences in other adverse reactions were observed between the two groups. The mean duration of fever in baloxavir group (1.43d) was significantly shorter than that in oseltamivir group (2.31d) [P < 0.001, 95%CI (0.7815, 0.9917)]. There were no differences in the mean duration of nasal congestion and runny nose, sore throat, cough, and muscle soreness between two groups.
    UNASSIGNED: The incidence of nausea and vomiting is lower with baloxavir compared to oseltamivir, and the duration for complete fever reduction is shorter with baloxavir than with oseltamivir. The results indicate that baloxavir is well tolerated and effective in Chinese children.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:莱姆病在加拿大和美国继续蔓延,没有单一的干预措施可能遏制这一流行病。
    方法:我们提出了一个平台来定量评估Ixodescap虫管理方法的子集的有效性。该平台使我们能够评估不同对照治疗的影响,单独进行(单一干预)或联合进行(联合努力),不同的时间和持续时间。干预措施包括三种不同组合的低环境毒性措施,即白尾鹿(Odocoileusvirginianus)种群的减少,播种面积-昆虫病原真菌绿僵菌的应用,和基于氟虫腈的啮齿动物目标诱饵盒。为了评估这些控制措施的影响,我们对从雷丁镇的住宅物业收集的数据校准了基于过程的数学模型,康涅狄格州西南部,从2013年到2016年,进行了一项减少肩胛骨若虫的综合蜱管理计划。我们从机械上估计了三种治疗方法的参数,模拟干预措施的多种组合和时机,并计算若虫峰和物候曲线下面积的减少百分比。
    结果:模拟输出表明,三种治疗组合和诱饵盒-鹿减少组合对抑制肩胛骨若虫的总体影响最大。当实施更多的年数时,所有(单一或组合)干预措施都更有效。如果实施至少4年,与没有干预的情况相比,大多数干预措施(除了单独使用昆虫病原真菌)预计会大大降低若虫峰。最后,我们确定了在住宅庭院中应用昆虫病原真菌的最佳时期,取决于应用程序的数量。
    结论:计算机模拟是确定个人和组合滴答管理方法的最佳部署的强大工具,这可以协同促进短期到长期,costeffective,以及在综合蜱管理(ITM)干预措施中可持续控制蜱传疾病。
    BACKGROUND: Lyme disease continues to expand in Canada and the USA and no single intervention is likely to curb the epidemic.
    METHODS: We propose a platform to quantitatively assess the effectiveness of a subset of Ixodes scapularis tick management approaches. The platform allows us to assess the impact of different control treatments, conducted either individually (single interventions) or in combination (combined efforts), with varying timings and durations. Interventions include three low environmental toxicity measures in differing combinations, namely reductions in white-tailed deer (Odocoileus virginianus) populations, broadcast area-application of the entomopathogenic fungus Metarhizium anisopliae, and fipronil-based rodent-targeted bait boxes. To assess the impact of these control efforts, we calibrated a process-based mathematical model to data collected from residential properties in the town of Redding, southwestern Connecticut, where an integrated tick management program to reduce I.xodes scapularis nymphs was conducted from 2013 through 2016. We estimated parameters mechanistically for each of the three treatments, simulated multiple combinations and timings of interventions, and computed the resulting percent reduction of the nymphal peak and of the area under the phenology curve.
    RESULTS: Simulation outputs suggest that the three-treatment combination and the bait boxes-deer reduction combination had the overall highest impacts on suppressing I. scapularis nymphs. All (single or combined) interventions were more efficacious when implemented for a higher number of years. When implemented for at least 4 years, most interventions (except the single application of the entomopathogenic fungus) were predicted to strongly reduce the nymphal peak compared with the no intervention scenario. Finally, we determined the optimal period to apply the entomopathogenic fungus in residential yards, depending on the number of applications.
    CONCLUSIONS: Computer simulation is a powerful tool to identify the optimal deployment of individual and combined tick management approaches, which can synergistically contribute to short-to-long-term, costeffective, and sustainable control of tick-borne diseases in integrated tick management (ITM) interventions.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    在维生素D缺乏风险增加的患者中研究了每天补充维生素D的剂量高于正常剂量(达到上限值)和间歇(每周一次或两次)剂量。使用PubMed数据库,对已发表的随机对照试验和其他研究进行了彻底的搜索,并对结果进行了分析。这篇综述概述了每天7000IU的使用情况,每周30,000IU或每周两次,每周50,000IU的维生素D,用于在维生素D缺乏高危患者中获得并维持25(OH)D浓度至少30ng/mL。上述剂量应考虑在成人肥胖,肝病或吸收不良综合征,或者多病患者,主要是需要多种药物治疗的老年人,包括影响维生素D代谢的药物.7000IU/天的简单时间表,30,000IU/周或每周两次,我们还考虑了5万IU/周用于维生素D缺乏风险增加的患者.在不监测25(OH)D的情况下,7000IU的每日剂量或30,000IU/周的间歇剂量应视为预防或维持剂量,主要是肥胖患者,肝病患者和吸收不良综合征患者。对于治疗这些组中可能的维生素D缺乏而不评估25(OH)D,每周两次30,000IU或每周50,000IU的间歇剂量应考虑仅在6-8周期间。较高的日剂量或上述建议的间歇剂量是有效的,根据患者的喜好安全和反应灵敏。
    Daily vitamin D supplementation using higher than normal dosing (up to the upper limit value) and intermittent (once or twice per week) dosing were studied in patients with increased risk of vitamin D deficiency. Using a PubMed database, a thorough search for published randomized controlled trials and other studies was conducted, and the results were analyzed. This review provides an overview of the use of 7000 IU daily, 30,000 IU per week or twice weekly, and 50,000 IU weekly of vitamin D for obtaining and maintaining 25(OH)D concentrations of at least 30 ng/mL in patients at high risk of vitamin D deficiency. The abovementioned dosages should be considered in adults with obesity, liver disease or malabsorption syndromes, or multi-diseased patients, mainly seniors requiring multi-drug treatment, including drugs affecting vitamin D metabolism. The simple schedules of 7000 IU/day, 30,000 IU/week or twice weekly, and 50,000 IU/week for use by patients with an increased risk of vitamin D deficiency were provided for consideration. Without monitoring of 25(OH)D, daily doses of 7000 IU or intermittent doses of 30,000 IU/week should be considered for a prolonged time as prophylactic or maintenance doses, mainly in obese patients, patients with liver disease and patients with malabsorption syndromes. For the treatment of possible vitamin D deficiency without assessment of 25(OH)D in these groups, intermittent doses of 30,000 IU twice weekly or 50,000 IU per week should be considered for a 6-8-week period only. The higher daily doses or the intermittent doses suggested above are effective, safe and responsive based on patient\'s preferences.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    此官方指南由DGGG发布和协调,OEGGG和SGGG与其他医学协会的参与。目的是根据对相关文献的评估,提供非激素避孕形式的共识概述。这些总结的陈述和建议的第一部分介绍了自然计划生育方法,例如哺乳期闭经,屏障方法和性交中断。第二部分重点介绍宫内节育器和绝育。方法本S2k指南是由来自不同医学专业的代表成员代表DGGG指南委员会制定的,OEGGG和SGGG使用结构化共识过程。建议该指南提供了关于适应症的建议,使用安全,好处,以及不同方法的局限性,以及提供非激素避孕建议和其他方面的建议。本摘要提供了有关宫内节育器以及女性和男性绝育的建议和声明。
    Aim This official guideline was published and coordinated by the DGGG, OEGGG and SGGG with the involvement of other medical societies. The aim was to provide a consensus-based overview of non-hormonal forms of contraception based on an evaluation of the relevant literature. The first part of these summarized statements and recommendations presents natural family planning methods such as lactational amenorrhea, barrier methods and coitus interruptus. The second part focuses on intrauterine devices and sterilization. Methods This S2k-guideline was developed by representative members from different medical professions on behalf of the guidelines commission of the DGGG, OEGGG and SGGG using a structured consensus process. Recommendations The guideline provides recommendations on the indications for, safety of use, benefits, and limitations of the different methods as well as recommendations on providing advice and other aspects of non-hormonal contraception. This summary presents recommendations and statements about intrauterine devices and female and male sterilization.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    此官方指南由DGGG发布和协调,OEGGG和SGGG与其他医学协会的参与。目的是根据对相关文献的评估,提供非激素避孕形式的共识概述。这些总结的陈述和建议的第一部分介绍了自然计划生育方法,例如哺乳期闭经,屏障方法和性交中断。第二部分将重点介绍宫内节育器和灭菌方法。方法本S2k指南是由来自不同医学专业的代表成员代表DGGG指南委员会制定的,OEGGG和SGGG使用结构化共识过程。建议该指南提供了关于适应症的建议,使用安全,好处,以及不同方法的局限性,以及提供非激素避孕建议和其他方面的建议。自然计划生育方法,哺乳期闭经,讨论了屏障方法和性交中断。
    Aim This official guideline was published and coordinated by the DGGG, OEGGG and SGGG with the involvement of other medical societies. The aim was to provide a consensus-based overview of non-hormonal forms of contraception based on an evaluation of the relevant literature. The first part of these summarized statements and recommendations presents natural family planning methods such as lactational amenorrhea, barrier methods and coitus interruptus. The second part will focus on intrauterine devices and sterilization methods. Methods This S2k-guideline was developed by representative members from different medical professions on behalf of the guidelines commission of the DGGG, OEGGG and SGGG using a structured consensus process. Recommendations The guideline provides recommendations on the indications for, safety of use, benefits, and limitations of the different methods as well as recommendations on providing advice and other aspects of non-hormonal contraception. Natural family planning methods, lactational amenorrhea, barrier methods and coitus interruptus are discussed.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    带回肠导管的根治性膀胱切除术是目前治疗肌层浸润性膀胱癌的主要方法,也是一种高风险的手术。现有研究对该方法的疗效和安全性的针对性评估有限。而适合此手术的患者人群仍未明确定义。我们试图纵向分析不同年龄亚组的回肠导管根治性膀胱切除术的疗效和安全性差异,以评估选择此手术时是否应将年龄因素用作排除标准。
    我们回顾性分析了2014年2月至2023年10月在哈尔滨医科大学附属肿瘤医院接受RC和IC治疗的MIBC患者的临床病理资料。此外,我们利用SEER数据库(2000-2020)的临床和病理数据对我们的发现进行外部验证.患者分为老年组(诊断时≥70岁)和非老年组(<70岁)。统计分析包括t检验,连续数据的非参数检验,分类数据的卡方检验,和Kaplan-Meier生存分析。
    在这项研究中,包括152名患者:119名被归类为非老年人,33名被归类为老年人。对于外部验证,对SEER数据库中416例患者的数据进行了分析,172人被归类为非老年人,244人被归类为老年人。结果表明,老年患者术后更有可能需要ICU转移,但造口炎症的发生率较低。此外,我们中心的数据和SEER数据库的外部验证均显示,老年人组和非老年人组之间的癌症特异性生存率(CSS)一致.RC与IC在老年和非老年患者中的疗效相当。
    对于纵向年龄亚组,RC与IC用于老年和非老年MIBC均具有良好的疗效和安全性。术后生活质量良好。尽管老年患者存在手术和围手术期风险,与非老年患者相比无显著性差异。在需要RC治疗膀胱癌的老年患者中,IC应该仍然是尿流改道的首选模式,老年不应作为IC的绝对排除标准。
    UNASSIGNED: Radical cystectomy with ileal conduit is the current mainstay of treatment for muscle-invasive bladder cancer and is also a high-risk procedure. Existing studies have limited targeted assessment of the efficacy and safety of this procedure, and the patient population appropriate for this procedure is still poorly defined. We sought to longitudinally analyze differences in the efficacy and safety of radical cystectomy with ileal conduit by age subgroups to assess whether the age factor should be used as an exclusion criterion when selecting this procedure.
    UNASSIGNED: We retrospectively examined the clinicopathological data of patients with MIBC treated with RC with IC at the Cancer Hospital of Harbin Medical University between February 2014 and October 2023. Additionally, we utilized clinical and pathological data from the SEER database (2000-2020) for external validation of our findings. Patients were categorized into elderly (≥70 years at diagnosis) and non-elderly (<70 years) groups. Statistical analyses included t-tests, non-parametric tests for continuous data, chi-square tests for categorical data, and Kaplan-Meier survival analysis.
    UNASSIGNED: In this study, 152 patients were included: 119 were categorized as non-elderly and 33 as elderly. For external validation, data from 416 patients in the SEER database were analyzed, with 172 classified as non-elderly and 244 as elderly. The results indicated that elderly patients were more likely to require ICU transfer postoperatively but exhibited a lower incidence of stoma inflammation. Additionally, both the data from our center and the external validation from the SEER database showed a concordance in cancer-specific survival (CSS) between the elderly and non-elderly groups. The efficacy of RC with IC was comparable in both elderly and non-elderly patients.
    UNASSIGNED: For longitudinal age subgroups, RC with IC for both elderly and non-elderly MIBC had good efficacy and safety, and good quality of life after surgery. Although there are surgical and perioperative risks in elderly patients, there is no significant difference compared with non-elderly patients. In elderly patients requiring RC for bladder cancer, IC should remain the preferred mode of urinary diversion, and old age should not be used as an absolute exclusion criterion for IC.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    BaloxavirMarboxil是一种口服小分子抗病毒药物,用于治疗流感。虽然BaloxavirMarboxil的疗效和安全性已经在广泛的临床试验中得到了彻底的表征,关于BaloxavirMarboxil在现实世界中的有效性的研究仍然很少。
    我们进行了一次全面调查,观察,多中心研究纳入华东地区接受巴洛沙韦或奥司他韦治疗的无并发症流感门诊患者。主要终点是从治疗到缓解所有流感症状的时间(TTAIS)。次要终点包括在流感持续期间从治疗到缓解发热(TTAF)和家庭传播的时间。
    共纳入509例患者。BaloxavirMarboxil组和奥司他韦组的TTAIS中位数为28.0h(IQR,20.0至50.0)和48.0小时(IQR,30.0到67.0),分别。BaloxavirMarboxil组和奥司他韦组的TTAF中位数为18h(IQR,10.0-24.0)和30.0h(IQR,19.0-48.0)。在COX多变量分析中,BaloxavirMarboxil减少了流感症状的持续时间(HR=1.36[95CI:1.12-1.64],p=0.002)和发热持续时间(HR=1.93[95CI:1.48-2.52],p<0.001)与奥司他韦相比。当在症状发作后12-48小时内给予抗病毒药物时,与奥司他韦组相比,巴洛沙韦组的TTAIS显著缩短.两组之间的不良事件发生率没有显着差异(p=0.555)。
    在缓解无并发症流感门诊患者的流感症状方面,巴洛沙韦优于奥司他韦。我们的研究结果表明,与奥司他韦相比,BaloxavirMarboxil可能更适合症状发作后12-48h的流感患者。
    UNASSIGNED: Baloxavir Marboxil is a per oral small-molecule antiviral for the treatment of influenza. While the efficacy and safety of Baloxavir Marboxil have been thoroughly characterized across an extensive clinical trial, studies on the effectiveness of Baloxavir Marboxil in a real-world setting are still scarce.
    UNASSIGNED: We conducted an ambispective, observational, multi-center study that enrolled uncomplicated in-fluenza outpatients treated with Baloxavir Marboxil or Oseltamivir in East China. The primary endpoint was time from treatment to alleviation of all influenza symptoms (TTAIS). The secondary endpoints included time from treatment to alleviation of fever (TTAF) and household transmission during the duration of influenza.
    UNASSIGNED: A total of 509 patients were enrolled. The median TTAIS in the Baloxavir Marboxil group and the Oseltamivir group was 28.0  h (IQR, 20.0 to 50.0) and 48.0  h (IQR, 30.0 to 67.0), respectively. The median TTAF in the Baloxavir Marboxil group and the Oseltamivir group was 18  h (IQR, 10.0-24.0) and 30.0  h (IQR, 19.0-48.0). In the COX multivariable analysis, Baloxavir Marboxil reduced the duration of influenza symptoms (HR  =  1.36 [95%CI:1.12-1.64], p =  0.002) and the duration of fever (HR  =  1.93 [95%CI:1.48-2.52], p < 0.001) compared to Oseltamivir. When antiviral drugs were given within 12-48  h after symptom onset, the Baloxavir Marboxil group had a significantly shorter TTAIS compared to the Oseltamivir group. There was no significant difference in the rate of adverse events between the two group (p = 0.555).
    UNASSIGNED: Baloxavir Marboxil was superior to Oseltamivir in alleviating influenza symptoms in outpatients with uncomplicated influenza. Our findings suggested that compared to Oseltamivir, Baloxavir Marboxil might be more appropriate for patients with influenza 12- 48 h after symptom onset.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景龋齿和牙龈炎是可预防的疾病,在全球儿童中仍然非常普遍,虽然通过口腔细菌的转移通常从母亲到孩子传播,不同于通过直接接触传播的传染病,空气,或向量。与传染病不同,通过适当的口腔卫生习惯和饮食调整,可以有效预防龋齿和牙龈炎。口腔健康教育(OHE)旨在改善口腔卫生习惯并减少口腔健康问题。然而,缺乏OHE中多个主题对学龄前儿童影响的证据。这项研究旨在研究通过视频演示提供的单主题与多主题OHE对学龄前儿童牙菌斑和牙龈状况的影响。方法对5岁和6岁健康学龄前儿童进行平行五臂整群随机对照试验。患有慢性疾病的儿童,残疾人,或可能影响其口腔健康或参与OHE干预能力的疾病被排除.OHE干预被分配给10个班级中的8个班级的儿童作为干预组,而两个班级作为对照组,不接受干预。干预组接受了一个,两个,或使用专门开发的动画视频的三个口腔健康主题,马来语:刷牙技巧(T),刷牙技术和糖消耗对口腔健康(TS)的影响,龋齿和牙龈炎(TP)的刷牙技术和发病机理,和刷牙技术,糖消耗对口腔健康的影响,龋齿和牙龈炎(TSP)的发病机制。菌斑和牙龈评分,随着口腔健康知识,态度,和技能(KAS),在干预前后进行记录。报告遵循CONSORT指南。分析包括描述性统计,单向方差分析,效果大小,和5%显著性水平的多变量协方差分析(MANCOVA)。结果160名参与者平均分为5组(n=32)。牙菌斑或牙龈评分无基线差异。各组干预后菌斑和牙龈评分均显著降低(p<0.05),效果大小范围从-1.1到-0.7。没有观察到口腔健康(KAS)的变化。干预组的菌斑和牙龈评分明显低于对照组(p<0.05),但调整基线KAS后,两者之间没有差异(p>0.05)。结论这项研究表明,在学龄前儿童的OHE计划中包括多个主题不一定能改善口腔健康结果。简化的OHE可能在时间上更有利,成本,人力资源,和组织。
    Background Dental caries and gingivitis are preventable diseases that remain highly prevalent among children globally and, while transmissible through the transfer of oral bacteria typically from mother to child, differ from communicable diseases that are spread through direct contact, air, or vectors. Unlike communicable diseases, dental caries and gingivitis can be effectively prevented through proper oral hygiene practices and dietary modifications. Oral health education (OHE) intends to improve oral hygiene practices and reduce oral health problems. However, evidence of the impact of multiple topics in OHE on preschool children is lacking. This study aimed to examine the effects of single- versus multiple-topic OHE delivered via video presentations on the plaque and gingival status of preschool children. Methods A parallel five-arm cluster randomized controlled trial was conducted on healthy preschool children aged five and six years. Children with chronic illnesses, disabilities, or conditions that could affect their oral health or ability to participate in the OHE intervention were excluded. OHE interventions were given to children from eight of the 10 classes assigned as intervention groups, while two classes served as the control group and received no intervention. The intervention groups received one, two, or three oral health topics using specially developed animation videos, in Malay language: toothbrushing technique (T), toothbrushing technique and the effects of sugar consumption on oral health (TS), toothbrushing technique and pathogenesis of dental caries and gingivitis (TP), and toothbrushing technique, the effects of sugar consumption on oral health, and pathogenesis of dental caries and gingivitis (TSP). Plaque and gingival scores, along with oral health knowledge, attitude, and skills (KAS), were recorded before and after the intervention. The CONSORT guidelines were followed in reporting. The analyses included descriptive statistics, one-way ANOVA, effect sizes, and multivariate analysis of covariance (MANCOVA) at a 5% significance level. Results A total of 160 participants were equally distributed into five groups (n = 32). There were no baseline differences in plaque or gingival scores. All groups showed significantly lower plaque and gingival scores post-intervention (p < 0.05), with effect sizes ranging from -1.1 to -0.7. No changes in oral health (KAS) were observed. The intervention groups had significantly lower plaque and gingival scores compared to the control group (p < 0.05), but no differences were found between them after adjusting for baseline KAS (p > 0.05). Conclusions This study suggests that including multiple topics in OHE programs for preschool children may not necessarily improve oral health outcomes. Simplified OHE may be more advantageous in terms of time, cost, human resources, and organization.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    简介:许多研究探索了尼马特雷韦-利托那韦和阿兹夫定对老年COVID-19患者的治疗效果。然而,这两种药物之间的直接比较仍然相对有限。本研究旨在比较这两种药物在中国老年早期感染患者中的安全性和有效性,为临床治疗提供策略。方法:纳入中国2022年冬季流行期间住院的老年COVID-19患者(年龄≥65岁),分为尼马特雷韦-利托那韦和阿兹夫定。人口统计,用药信息,实验室参数,并收集治疗结果.全因28天死亡率,增量循环阈值(ΔCt),核酸阴性转化时间,不良事件发生率定义为结局.倾向得分匹配(PSM),Kaplan-Meier,Cox比例风险模型,亚组分析,并选择列线图来评估结局.结果:共筛查了1,508例老年COVID-19患者。根据纳入和排除标准,1,075名患者符合该研究的条件。PSM之后,纳入研究的老年COVID-19患者的最终人数为375例,两组之间的人口学特征无显著差异(p>0.05).与阿兹夫定组相比,Nirmatrelvir-Ritonavir组的多种不良事件发生率较高(12.8%vs5.2%,p=0.009)。Nirmatrelvir-利托那韦组与肾功能异常相关的不良事件发生率高于Azvudine组(13.6%vs7.2%,p=0.045)。两组在全因28天死亡率方面没有显着差异(HR=1.020,95%CI:0.542-1.921,p=0.951),而核酸阴性转化时间(HR=1.659,95%CI:1.166-2.360,p=0.005)和ΔCt值(HR=1.442,95%CI:1.084-1.918,p=0.012)存在显著差异。结论:阿兹夫定和尼马特雷韦-利托那韦在降低死亡风险方面具有相当的有效性。Azvudine在核酸阴性转化时间和病毒清除方面可能表现更好,并且在老年患者中显示出更好的安全性。需要更大样本量的进一步研究来验证结果。
    Introduction: Numerous studies have explored the treatment outcomes of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19. However, direct comparisons between these two drugs are still relatively limited. This study aims to compare the safety and effectiveness of these two drugs in Chinese older patients with early infection to provide strategies for clinical treatment. Methods: Older COVID-19 patients (age ≥65) hospitalized during the winter 2022 epidemic in China were included and divided into Nirmatrelvir-Ritonavir and Azvudine. Demographics, medication information, laboratory parameters, and treatment outcomes were collected. All-cause 28-day mortality, delta cycle threshold (ΔCt), nucleic acid negative conversion time, and incidence of adverse events were defined as outcomes. Propensity score matching (PSM), Kaplan-Meier, Cox proportional hazards model, subgroup analysis, and nomograms were selected to evaluate the outcomes. Results: A total of 1,508 older COVID-19 patients were screened. Based on the inclusion and exclusion criteria, 1,075 patients were eligible for the study. After PSM, the final number of older COVID-19 patients included in the study was 375, and there were no significant differences in demographic characteristics between the two groups (p > 0.05). Compared to the Azvudine group, the Nirmatrelvir-Ritonavir group showed a higher incidence of multiple adverse events (12.8% vs 5.2%, p = 0.009). The incidence of adverse events related to abnormal renal function was higher in the Nirmatrelvir-Ritonavir group compared to the Azvudine group (13.6% vs 7.2%, p = 0.045). There were no significant differences between the two groups in terms of all-cause 28-day mortality (HR = 1.020, 95% CI: 0.542 - 1.921, p = 0.951), whereas there were significant differences in nucleic acid negative conversion time (HR = 1.659, 95% CI: 1.166 - 2.360, p = 0.005) and ΔCt values (HR = 1.442, 95% CI: 1.084 - 1.918, p = 0.012). Conclusion: Azvudine and Nirmatrelvir-Ritonavir have comparable effectiveness in reducing mortality risk. Azvudine may perform better in nucleic acid negative conversion time and virus clearance and shows slightly better safety in older patients. Further studies with a larger sample size were needed to validate the result.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号